Skip to content

Study · Not a test of the peptide alone · 2025

2 results

High BMI z-Scores from Different Growth References Are Not Comparable: An Example from a Weight Management Trial with an Anti-Obesity Medication in Pubertal Adolescents with Obesity.

Hales CM, Ogden CL, Freedman DS, Sahu K, Hale PM, Mamadi RK, Kelly AS

Childhood obesity (Print)12 Jul 2024Cited by 1 (Europe PMC)

PMID38995874 (opens in a new tab)PMCIDPMC12422332 (opens in a new tab)DOI10.1089/chi.2024.0248 (opens in a new tab)PepBankPUB-38995874
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneOther designOther

    In a reanalysis of a liraglutide study in pubertal adolescents with obesity, overall BMI z-score estimates varied 2-fold, from -0.13 with CDC 2000 to -0.26 with WHO references.

    In plain wordsIn adolescents with obesity in a liraglutide-study reanalysis, overall BMI z-score estimates differed between CDC 2000 and WHO references.

    Peptide
    Liraglutide
    Outcome
    Not applicableBMI z-score treatment difference overall
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    BMI z-score treatment difference
    −0.13
    CDC 2000 overall
    BMI z-score treatment difference
    −0.26
    WHO overall

    Source sentences

    Summary
    BMI z-score treatment differences varied 2-fold from -0.13 (CDC 2000) to -0.26 (WHO) overall and varied almost 4-fold from -0.05 (CDC 2000) to -0.19 (WHO) among adolescents with high baseline BMI z-score.
    1 context sentence
    Summary · context
    This study reanalyzed data from a weight management clinical study of liraglutide in pubertal adolescents with obesity using growth references from CDC 2000, CDC Extended, World Health Organization (WHO), and International Obesity Task Force.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneOther designOther

    In a liraglutide-study reanalysis of pubertal adolescents with obesity and high baseline BMI z-score, estimates varied almost 4-fold, from -0.05 with CDC 2000 to -0.19 with WHO.

    In plain wordsIn adolescents with obesity and high initial BMI z-score, liraglutide-study estimates differed between CDC 2000 and WHO references.

    Peptide
    Liraglutide
    Outcome
    Not applicableBMI z-score treatment difference in high baseline BMI z-score
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    BMI z-score treatment difference
    −0.05
    CDC 2000 high baseline BMI z-score
    BMI z-score treatment difference
    −0.19
    WHO high baseline BMI z-score

    Source sentences

    Summary
    BMI z-score treatment differences varied 2-fold from -0.13 (CDC 2000) to -0.26 (WHO) overall and varied almost 4-fold from -0.05 (CDC 2000) to -0.19 (WHO) among adolescents with high baseline BMI z-score.
    1 context sentence
    Summary · context
    This study reanalyzed data from a weight management clinical study of liraglutide in pubertal adolescents with obesity using growth references from CDC 2000, CDC Extended, World Health Organization (WHO), and International Obesity Task Force.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.